Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Hepatitis B virus infection in renal transplant recipients
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Volume 60, Issue 2, Pages (February 2014)
Volume 59, Issue 1, Pages (July 2013)
The impact of hepatitis E in the liver transplant setting
Inflammasomes in liver diseases
Volume 61, Issue 4, Pages (October 2014)
Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Volume 67, Issue 2, Pages (August 2017)
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
Volume 42, Issue 6, Pages (June 2005)
R. Cavallo  Clinical Microbiology and Infection 
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Immigration and viral hepatitis
Hepatitis B and C virus-related carcinogenesis
Liver transplantation for hepatitis B virus-related liver disease: Indications, prevention of recurrence and results  Bruno Roche, Didier Samuel  Journal.
Living donor liver transplantation: is the hype over?
Reply to: “DCD consensus and futility in liver transplantation”
Introduction The American Journal of Medicine
Volume 69, Issue 2, Pages (August 2018)
Hepatitis B infection in heart transplant recipients
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Volume 68, Issue 1, Pages (January 2018)
Hepatitis C core protein – The “core” of immune deception?
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Autophagy in the liver Journal of Hepatology
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 61, Issue 1, Pages S45-S57 (November 2014)
Volume 50, Issue 2, Pages (February 2009)
Stephen Locarnini, Angelos Hatzakis, Ding-Shinn Chen, Anna Lok 
Quantitation of anti-HBe antibodies in anti-HBc-positive liver donors
Hepatitis B Immunoglobulin and Lamivudine Improve Hepatitis B–Related Outcomes After Liver Transplantation: Meta-Analysis  Rohit Loomba, Ayana K. Rowley,
Volume 42, Issue 4, Pages (April 2005)
Hepatitis B and C virus-related carcinogenesis
EASL Clinical Practice Guidelines on hepatitis E virus infection
Treatment of hepatitis B in patients with chronic kidney disease
Volume 50, Issue 4, Pages (April 2009)
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Volume 67, Issue 5, Pages (November 2017)
Volume 56, Issue 6, Pages (June 2012)
Immigration and viral hepatitis
Volume 57, Issue 3, Pages (September 2012)
Volume 63, Issue 1, Pages (July 2015)
Volume 51, Issue 2, Pages (August 2009)
The use of hemospray in portal hypertensive bleeding; a case series
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence  Christian Toso, Gilles Mentha, Pietro.
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Donor-recipient matching: Myths and realities
Chimeric mouse model of hepatitis B virus infection
MELD: the holy grail of organ allocation?
Volume 56, Issue 3, Pages (March 2012)
Outcomes in liver transplantation: Does sex matter?
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Liver grafts from anti-hepatitis B core positive donors: A systematic review  Evangelos Cholongitas, George V. Papatheodoridis, Andrew K. Burroughs  Journal of Hepatology  Volume 52, Issue 2, Pages 272-279 (February 2010) DOI: 10.1016/j.jhep.2009.11.009 Copyright © 2009 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Risk ofde novohepatitis B virus (HBV) infection in HBsAg-negative recipients who received liver grafts from anti-HBc positive donors and no HBV prophylaxis after liver transplantation (LT) in relation to their HBV serological status before transplant. Journal of Hepatology 2010 52, 272-279DOI: (10.1016/j.jhep.2009.11.009) Copyright © 2009 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Risk ofde novohepatitis B virus (HBV) infection in HBsAg-negative recipients of liver grafts from anti-HBc positive donors in relation to their pre-transplant HBV serological status and the use of HBV prophylaxis after liver transplantation (LT). Journal of Hepatology 2010 52, 272-279DOI: (10.1016/j.jhep.2009.11.009) Copyright © 2009 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Risk ofde novohepatitis B virus (HBV) infection in HBsAg-negative recipients who received liver grafts from anti-HBc positive donors and HBV prophylaxis after liver transplantation (LT) in relation to their pre-transplant HBV serological status and the type of post-transplant HBV prophylaxis.HBIG, hepatitis B immunoglobulin; LAM, lamivudine. Journal of Hepatology 2010 52, 272-279DOI: (10.1016/j.jhep.2009.11.009) Copyright © 2009 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Proposed algorithm for allocation and management of anti-HBc positive liver grafts. Such grafts should be first offered to HBsAg positive, then to anti-HBc and/or anti-HBs positive and lastly to HBV naive (both anti-HBc and anti-HBs negative) recipients. LT, liver transplantation; HBIG, hepatitis B immunoglobulin; LAM, lamivudine. Journal of Hepatology 2010 52, 272-279DOI: (10.1016/j.jhep.2009.11.009) Copyright © 2009 European Association for the Study of the Liver Terms and Conditions